Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer
暂无分享,去创建一个
L. Moldawer | S. Wallet | T. George | Kien Pham | S. Hughes | J. Trevino | K. Behrns | Ryan M. Thomas | Chen Liu | Christina L. Graves | Song Han | D. Gonzalo | Daniel Delitto | Andrea E. Knowlton | Chelsey Perez | K. Behrns | D. Delitto
[1] C. Clendenin,et al. Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. , 2015, Gastroenterology.
[2] S. Pothula,et al. Pancreatic cancer: The microenvironment needs attention too! , 2015, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
[3] D. Tuveson,et al. Stromal biology and therapy in pancreatic cancer: a changing paradigm , 2015, Gut.
[4] G. Sarosi,et al. Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. , 2015, The American journal of pathology.
[5] P. Kris-Etherton,et al. In vitro Production of IL-6 and IFN-γ is Influenced by Dietary Variables and Predicts Upper Respiratory Tract Infection Incidence and Severity Respectively in Young Adults , 2015, Front. Immunol..
[6] E. Furth,et al. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma , 2015, Cancer Immunology Research.
[7] R. Jesenofsky,et al. Desmoplasia and Chemoresistance in Pancreatic Cancer , 2014, Cancers.
[8] Gisele Monteiro,et al. Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. , 2014, European journal of pharmacology.
[9] N. Jamieson,et al. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival , 2014, Oncotarget.
[10] Benjamin D. Smith,et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.
[11] T. Giese,et al. Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer , 2014, Clinical Cancer Research.
[12] Derek S. Chan,et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.
[13] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[14] S. Sebti,et al. Selective Disruption of Rb–Raf-1 Kinase Interaction Inhibits Pancreatic Adenocarcinoma Growth Irrespective of Gemcitabine Sensitivity , 2013, Molecular Cancer Therapeutics.
[15] L. Diaz,et al. Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer , 2013, Journal of immunotherapy.
[16] A. Levchenko,et al. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. , 2012, The Journal of clinical investigation.
[17] S. Chellappan,et al. Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma. , 2012, Neoplasia.
[18] M. Choudhry,et al. Activation of Toll-Like Receptor 2 Prevents Suppression of T-Cell Interferon γ Production by Modulating p38/Extracellular Signal-Regulated Kinase Pathways following Alcohol and Burn Injury , 2012, Molecular medicine.
[19] Alexander A. Fingerle,et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications , 2012, Nature Reviews Gastroenterology &Hepatology.
[20] N. Jhala,et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.
[21] O. Wolkenhauer,et al. Studies on mechanisms of interferon-gamma action in pancreatic cancer using a data-driven and model-based approach , 2011, Molecular Cancer.
[22] James O. Jones,et al. Suppression of Antitumor Immunity by Stromal Cells Expressing , 2022 .
[23] L. Sherman,et al. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. , 2010, Cancer research.
[24] S. Rosenberg,et al. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.
[25] Huamin Wang,et al. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. , 2009, Cancer research.
[26] Matthias Schäfer,et al. Cancer as an overhealing wound: an old hypothesis revisited , 2008, Nature Reviews Molecular Cell Biology.
[27] G. Gallick,et al. Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells , 2007, Annals of Surgical Oncology.
[28] D. Tuveson,et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.
[29] Helmut Friess,et al. Pancreatic cancer microenvironment , 2007, International journal of cancer.
[30] B. Shalmon,et al. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. , 2007, Cancer research.
[31] Michael G. Johnson,et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. , 2006, Cancer research.
[32] G. Willimsky,et al. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance , 2005, Nature.
[33] J. Trevino,et al. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. , 2005, Cancer research.
[34] E. Jaffee,et al. Immunotherapy for pancreatic cancer — science driving clinical progress , 2005, Nature Reviews Cancer.
[35] R. Hruban,et al. Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients , 2004, The Journal of experimental medicine.
[36] T. Manabe,et al. Pivotal Role of CXCR3 in Melanoma Cell Metastasis to Lymph Nodes , 2004, Cancer Research.
[37] Tasuku Honjo,et al. PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.
[38] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[39] Verhoef,et al. Lymphocyte Stimulation by CD3‐CD28 Enables Detection of Low T Cell Interferon‐γ and Interleukin‐4 Production in Rheumatoid Arthritis , 1999, Scandinavian journal of immunology.
[40] I. Fidler,et al. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. , 1999, Neoplasia.
[41] R. Schmid,et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. , 1998, Gastroenterology.
[42] R. Schreiber,et al. Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .
[43] S. Ramakrishna,et al. Immune system: a double-edged sword in cancer , 2013, Inflammation Research.
[44] M. Serio,et al. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. , 2001, The Journal of clinical investigation.
[45] R. Schreiber,et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[46] U. Boehm,et al. Cellular responses to interferon-gamma. , 1997, Annual review of immunology.